F
Forendo Pharma
Clinical stage drug development company focused on novel therapeutic solutions for women's health
About Forendo Pharma
Forendo Pharma is a clinical-stage drug development company specializing in innovative therapeutic solutions for endometriosis. Operating in the biopharmaceutical sector, Forendo Pharma leverages its proprietary HSD17B platform to develop novel treatments aimed at addressing unmet medical needs in women's health. The company primarily serves patients suffering from endometriosis, a condition characterized by painful symptoms due to tissue similar to the lining inside the uterus growing outside it. Forendo Pharma's business model focuses on research and development (R&D) to create groundbreaking drugs, which are then brought to market through strategic partnerships and collaborations with major pharmaceutical companies. Revenue is generated through licensing agreements, milestone payments, and potential future sales of approved therapies. The company's investors include Novo Seeds, Karolinska Development, Innovestor, Novartis Venture Fund, M Ventures, Vesalius Biocapital III Partners, and Sunstone Life Science Ventures.
Source: Dealroom company dataAt a glance
- Status
- Acquired
- Founded
- 2013
- Headquarters
- Turku, Finland
- Employees
- 19
- Open positions
- None listed
- Dealroom signal
- 71.3/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Drug Development, Patient Care, Biotech and Pharma, Hard Tech, DT and LS, science-based
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Nov 2021 | $75M | $75M | Organon | ↗ |
| EARLY VC✓Equity / VC | Jul 2019 | $5.6M | $23M | M Ventures · Vesalius Biocapital Partners · Novartis Venture Fund · Novo Holdings | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Forendo Pharma is 190 monthly website visits, down 13.6% over the last three months. Forendo Pharma's team grew 5.6% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
M Ventures
Novartis Venture Fund
Vesalius Biocapital Partners
Sunstone Life Science Ventures
Novo Holdings
Series B and later1 investor entered at this stage
Other known investors3 additional known investors
Organon
Innovestor
Karolinska Development
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Forendo Pharma on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Forendo Pharma’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.